Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)
- PMID: 8381211
- PMCID: PMC2916679
- DOI: 10.1038/361362a0
Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)
Abstract
Non-insulin-dependent diabetes mellitus (NIDDM, type 2 diabetes) is a disorder of glucose homeostasis characterized by hyperglycaemia, peripheral insulin resistance, impaired hepatic glucose metabolism, and diminished glucose-dependent secretion of insulin from pancreatic beta-cells. Glucagon-like-peptide-1(7-37) (GLP-1) is an intestinally derived hormone that may be useful for the treatment of NIDDM because it acts in vivo to increase the level of circulating insulin, and thus lower the concentration of blood glucose. This therapeutic effect may result from the ability of GLP-1 to compensate for a defect in the glucose signalling pathway that regulates insulin secretion from beta-cells. In support of this concept we report here that GLP-1 confers glucose sensitivity to glucose-resistant beta-cells, a phenomenon we term glucose competence. Induction of glucose competence by GLP-1 results from its synergistic interaction with glucose to inhibit metabolically regulated potassium channels that are also targeted for inhibition by sulphonylurea drugs commonly used in the treatment of NIDDM. Glucose competence allows membrane depolarization, the generation of action potentials, and Ca2+ influx, events that are known to trigger insulin secretion.
Figures



Similar articles
-
GLP-I(7-36) amide augments Ba2+ current through L-type Ca2+ channel of rat pancreatic beta-cell in a cAMP-dependent manner.Diabetes. 1997 Nov;46(11):1755-60. doi: 10.2337/diab.46.11.1755. Diabetes. 1997. PMID: 9356022
-
Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide.Diabetes. 1997 Apr;46(4):615-21. doi: 10.2337/diab.46.4.615. Diabetes. 1997. PMID: 9075801
-
Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors.Pflugers Arch. 1997 Sep;434(5):515-24. doi: 10.1007/s004240050431. Pflugers Arch. 1997. PMID: 9242714
-
Glucagon-like peptide-1 structure, function and potential use for NIDDM.Isr J Med Sci. 1997 Oct;33(10):690-5. Isr J Med Sci. 1997. PMID: 9397146 Review.
-
Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM.Diabetes. 1993 Sep;42(9):1219-25. doi: 10.2337/diab.42.9.1219. Diabetes. 1993. PMID: 8349031 Review.
Cited by
-
The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways.Sci Rep. 2016 May 31;6:26859. doi: 10.1038/srep26859. Sci Rep. 2016. PMID: 27240461 Free PMC article.
-
Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome.Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):141-6. doi: 10.1073/pnas.1216801110. Epub 2012 Dec 17. Proc Natl Acad Sci U S A. 2013. PMID: 23248313 Free PMC article.
-
Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1).Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13468-73. doi: 10.1073/pnas.0600655103. Epub 2006 Aug 28. Proc Natl Acad Sci U S A. 2006. PMID: 16938896 Free PMC article.
-
Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element.Diabetes. 2000 Jul;49(7):1156-64. doi: 10.2337/diabetes.49.7.1156. Diabetes. 2000. PMID: 10909973 Free PMC article.
-
Gut microbiota in human metabolic health and disease.Nat Rev Microbiol. 2021 Jan;19(1):55-71. doi: 10.1038/s41579-020-0433-9. Epub 2020 Sep 4. Nat Rev Microbiol. 2021. PMID: 32887946 Review.
References
-
- Unger RH, Foster DW. In: Williams Textbook of Endocrinology. Wilson JD, Foster DW, editors. Saunders; Philadelphia: 1992. pp. 1255–1333.
-
- Mojsov S, et al. J. biol. Chem. 1986;261:11880–11889. - PubMed
-
- Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF. Diabetes Care. 1992;15:270–276. - PubMed
-
- Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. New Eng. J. Med. 1992;326:1316–1322. - PubMed
-
- Gerich JE. New Engl. J. Med. 1989;321:1231–1245. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous